Quadrature Capital LTD T Scan Therapeutics, Inc. Transaction History
Quadrature Capital LTD
- $5.81 Trillion
- Q2 2025
A detailed history of Quadrature Capital LTD transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Quadrature Capital LTD holds 22,500 shares of TCRX stock, worth $25,649. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,500Holding current value
$25,649% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
79Shares Held
37.6MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.86MShares$8.96 Million3.37% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$5.96 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$5.09 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$3.17 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$2.45 Million0.0% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $21.6M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...